Shilpa Medicare LimitedSeptember 6, 2019

FDA 483 - Shilpa Medicare Limited - September 06, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Shilpa Medicare Limited

Record Details

Shilpa Medicare Limited in Polepally, India, a manufacturer of human drug products, was cited for deficiencies in its quality control laboratory. The inspection revealed that the firm did not follow its written stability testing program, leading to sample analyses exceeding allowed timelines. Additionally, insanitary conditions were observed for QC lab instruments and apparatus, contributing to a high rate of out-of-specification results.

Company: Shilpa Medicare Limited
Inspection Date: September 6, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Roger F. Zabinski (Investigator)

Open in Dashboard

ID · 454b93df-428c-4c44-a718-2062133d8ced